<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04733508</url>
  </required_header>
  <id_info>
    <org_study_id>NL63933.091.17</org_study_id>
    <nct_id>NCT04733508</nct_id>
  </id_info>
  <brief_title>Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes</brief_title>
  <acronym>GLP1R-T2D</acronym>
  <official_title>Glucagon Like Peptide 1 Receptor (GLP1R) Expression and Beta-cell Mass in Patients With Type 2 Diabetes - the Role of Glucose Homeostasis on Uptake of Beta-cell Tracer Exendin-4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Coimbra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Validation of the exendin-based beta cell imaging technique in patients with type 2 diabetes&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Reliable imaging biomarkers for non-invasive characterisation of beta-cell mass&#xD;
      (BCM) are needed to aid understanding regarding the relationship between beta-cell mass and&#xD;
      function during the course of type 2 diabetes (T2D). This study will provide critical&#xD;
      information necessary to validate the applicability of exendin-based imaging techniques in&#xD;
      patients with T2D. The characterization of beta-cells is currently limited to pancreatic&#xD;
      specimens available at autopsy, as in vivo pancreatic biopsy is associated with complications&#xD;
      unacceptable in clinical studies. To date, only measurements of circulating C-peptide and&#xD;
      insulin levels can be obtained, but these measures do not reflect beta-cell mass, only total&#xD;
      beta-cell function. Reliable imaging biomarkers for non-invasive characterisation of beta&#xD;
      cell mass are therefore needed. These biomarkers could also be used to validate novel&#xD;
      therapeutic strategies aimed to increase or preserve BCM or identify whether patients are&#xD;
      eligible for a certain therapeutic strategy (e.g. when certain amount of beta-cells is&#xD;
      required). One can also think of identifying early responders to therapies, to avoid&#xD;
      unnecessary drug use and the accompanying costs.&#xD;
&#xD;
      The objective of this study is to determine the specificity of Exendin-4 during the course of&#xD;
      T2D and to examine the role of glycemic control on the correlation between pancreatic&#xD;
      Exendin-4 uptake, BCM and GLP-1R expression in patients with T2D undergoing (partial)&#xD;
      pancreatectomy. This will allow examination of the role of glycemic control on exendin uptake&#xD;
      in humans, but also implementation of clinical guidelines for the interpretation of clinical&#xD;
      exendin-based scans in patients with T2D to avoid false interpretation of the scans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic exendin uptake 111In-DTPA exendin-4</measure>
    <time_frame>111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using ex vivo SPECTof the resected tissue one day after surgery</time_frame>
    <description>The pancreatic uptake of 111In-DTPA-exendin-4 will be quantified using ex vivo SPECT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic exendin uptake 111In-DTPA exendin-4</measure>
    <time_frame>111In-DTPA-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined with tissue autoradiography immediately after resection</time_frame>
    <description>The pancreatic uptake of 111In-DTPA-exendin-4 will be quantified using tissue autoradiography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta cell function</measure>
    <time_frame>The glucose tolerance test will be performed within a week before planned surgery</time_frame>
    <description>The beta cell function will be determined with a glucose tolerance test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood glucose levels</measure>
    <time_frame>Blood glucose levels will be continuously monitored a week prior to surgery</time_frame>
    <description>Glycemic control will be determined by monitoring blood glucose levels</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HbA1C levels</measure>
    <time_frame>HbA1C levels will be determined within a week before planned surgery</time_frame>
    <description>HbA1C levels will be determined as a measure of glycemic control</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pancreatic exendin uptake IRDye800CW-exendin-4</measure>
    <time_frame>IRDye800CW-exendin-4 injection will be performed a day before planned surgery, and uptake will be determined using microscopy in the excised tissue</time_frame>
    <description>Uptake of IRDye800CW-exendin4 will be visualized with microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene expression</measure>
    <time_frame>Gene expression will be determined in the excised pancreatic tissue immediately after resection</time_frame>
    <description>Gene expression levels will be determined with quantitative polymerase chain reaction (qPCR)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>111In-exendin-DTPA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of 111In-exendin-DTPA for subsequent localization of the tracer in excised tissue using autoradiography</description>
  </arm_group>
  <arm_group>
    <arm_group_label>exendin-IRDye800CW</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection of exendin-4-IRDye800CW for subsequent localization of the tracer in excised tissue using fluorescence microscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In-DTPA-exendin-4</intervention_name>
    <description>Injection of 111In-DTPA-exendin-4 and localization of the tracer in excised pancreatic tissue using autoradiography</description>
    <arm_group_label>111In-exendin-DTPA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IRDye800CW-exendin-4</intervention_name>
    <description>Injection of IRDye800CW-exendin-4 and localization of the tracer in excised pancreatic tissue using fluorescence microscopy</description>
    <arm_group_label>exendin-IRDye800CW</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for partial or complete pancreatectomy at Radboudumc&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with synthetic exendin or dipeptidyl-peptidase IV inhibitors within&#xD;
             the past 3 months&#xD;
&#xD;
          -  Breast feeding&#xD;
&#xD;
          -  Pregnancy or the wist to become pregnant within 6 months&#xD;
&#xD;
          -  Creatinine clearance below 40ml/min&#xD;
&#xD;
          -  Liver disease defined as aspartate aminotransferase of alanine aminotransferase level&#xD;
             of more than three times the upper limit of normal range&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sanne van Lith, PhD</last_name>
    <phone>0031243613813</phone>
    <email>sanne.vanlith@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martin Gotthardt, MD, prof</last_name>
    <email>Martin.Gotthardt@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanne van Lith, PhD</last_name>
      <phone>0031243613813</phone>
      <email>sanne.vanlith@radboudumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Martin Gotthardt, MD, Prof</last_name>
      <email>Martin.Gotthardt@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 2, 2021</study_first_posted>
  <last_update_submitted>January 28, 2021</last_update_submitted>
  <last_update_submitted_qc>January 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>nuclear imaging</keyword>
  <keyword>beta cell mass</keyword>
  <keyword>exendin-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

